“The clinical implications of PEEP during IMV have not been thoroughly investigated,” stated Dr Min-Seok Kim (Asan Medical Centre, South Korea) [1]. The HELP-AHF trial (NCT04853563) aimed to evaluate high and low PEEP in patients with acute HF who were in need of IMV. Participants were randomised 1:1 to high PEEP, starting at 8 cmH2O and increasing to 10 cmH2O, or low PEEP, starting at 5 cmH2O and lowered to 3 cmH2O. The study’s primary endpoint was ventilator-free days at 28 days of follow-up.
“The study was terminated early after enrolling 60 participants, due to a significant imbalance in in-hospital mortality and adverse events between the study arms,” said Dr Kim. In-hospital mortality was more frequently observed in participants in the low PEEP arm (20.7% vs 0.0%; P=0.02). There were also significantly more adverse events in the low PEEP group than in the high PEEP group (41.4% vs 6.7%; P=0.002), including higher rates of severe hypoxaemia, weaning failure, and tracheostomy. At the time of trial termination, ventilator-free days were more common in the high PEEP arm than in the low PEEP arm (25.5 vs 24.0; P=0.02).
Although the sample size of the HELP-AHF study was small, it appears that the high PEEP strategy leads to better health outcomes than the low PEEP strategy in this patient population.
- Kim M-S, et al. Comparison of high versus low positive end-expiratory pressure in mechanically ventilated patients with acute heart failure: a HELP-AHF randomised clinical trial. Hottest trials and trial updates (2), Heart Failure 2025, 17–20 May, Belgrade, Serbia.
Medical writing support was provided by Robert van den Heuvel.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« Consistent results for nexiguran ziclumeran across wildtype and variant ATTR-CM Next Article
Teduglutide helps to reach enteral autonomy in SBS-associated intestinal failure »
« Consistent results for nexiguran ziclumeran across wildtype and variant ATTR-CM Next Article
Teduglutide helps to reach enteral autonomy in SBS-associated intestinal failure »
Table of Contents: HFA 2025
Featured articles
FINEARTS-HF confirms: analysis suggests premature cessation of Finerenone is associated with risk and supports long-term treatment
New Therapies for Hypertrophic Cardiomyopathy
SEQUOIA-HCM: Aficamten effects consistent across regions
Large Trials, Big Impact
PRAISE-HFrEF: Is it safe to use GLP1-receptor agonists in clinically severe HF?
HELIOS-B: Health benefits of vutrisiran for ATTR-CM may increase over time
EMPEROR-Preserved: Diastolic dysfunction might predict response to empagliflozin
GALACTIC-HF: zooming in on efficacy data and subgroups
More Hot Trials from HFA
PREFER-HF: Is iron therapy helpful in HFpEF with iron deficiency?
SOGALDI-PEF: SGLT2 inhibitor plus MRA improves biomarker outcomes in HFp/mrEF
REDICAE: Diuretic withdrawal appears feasible in stable HFrEF
GLADIATOR: Anti-ulcer agent geranylgeranylacetone explored in HFpEF
High vs low positive end-expiratory pressure in IMV may impact survival
Gene Therapy and the Future of HF Management
Artificial intelligence in HF management
Consistent results for nexiguran ziclumeran across wildtype and variant ATTR-CM
New gene therapy for HFrEF passes phase 1 testing
MUSIC-HFpEF: Encouraging early results of novel gene therapy for HFpEF
Innovative Devices
FUTURE-HF: Novel IVC sensor may help control volume and improve function outcomes
C-MIC II: Cardiac microcurrent therapy in HFrEF
Updates on Finerenone
Real-world eligibility for finerenone: insights from the FIDELITY pooled analysis
FINEARTS-HF confirms: analysis suggests premature cessation of Finerenone is associated with risk and supports long-term treatment
FIVE-STAR: Mechanistic effects of finerenone in T2D plus CKD unravelled
Related Articles
March 22, 2023
ACC 2023 Highlights Podcast
January 11, 2023
Mindfulness programme contributes to office blood pressure lowering
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
